Inversago Pharma

Inversago Pharma is a preclinical-stage biotechnology company dedicated to developing first-in-class, peripherally-acting CB1 inverse agonists, focusing on new therapies based on CB1 blockade. The company aims to provide new treatment options to improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D), and diabetic nephropathy.